- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02846714
Family Lifestyle Actions and Risk Education Study (FLARE)
FLARE: Family Lifestyle Actions and Risk Education Study for Children With a Familial Risk for Melanoma
Study Overview
Detailed Description
Test the feasibility and acceptability of FLARE, a family-focused behavioral intervention that is designed to improve and maintain adherence to photoprotection (e.g., use of sunscreen) and screening (e.g., implementation of self skin exams). We expect that the feasibility of the intervention will be supported by at least 75% of participants attending at least 3 intervention sessions. We also expect that the acceptability of the intervention (e.g., overall satisfaction, ease of participation, perceived utility of intervention) will be supported by mean ratings that indicate adequate levels of acceptability across participants (e.g., mean rating of "satisfied" or "very satisfied" for overall satisfaction).
Pilot test the efficacy of the FLARE intervention with children at elevated risk for melanoma and their primary caregiver.
We will also explore the potential impact of the FLARE intervention on melanoma preventive behaviors among siblings of the child who receives the intervention, as well as the child's other parent/caregiver (if another parent/caregiver is available).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Children
- Are 8-17 years old AND
- Are at risk for melanoma due to having a first degree relative with a history of melanoma and/or at least 3 second or third degree relatives on the same side of the family with a history of melanoma AND/OR
- Have personally received genetic testing for the CDKN2A/p16 genetic mutation and/or has one or more family members who received CDKN2A/p16 testing
Adults
- Are at least 18 years old AND
- Are the primary caregiver for the child participating in the study (defined as the individual who is responsible for daily implementation of health-related tasks for the child) AND
- Have at least one child under age 18 who is living in the same household AND
- Have a personal history of melanoma and/or family history of melanoma) AND/OR
- Have personally received genetic testing for the CDKN2A/p16 genetic mutation and/or has one or more family members who received CDKN2A/p16 testing
Exclusion Criteria:
- Individuals who do not speak, read/write English will be excluded because FLARE involves regular interaction between study staff and research participants in English and completion of study questionnaires and interviews in English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: FLARE intervention
All FLARE participants enrolled will receive the intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent of Participants Retained Throughout Intervention as Assessed by Session Attendance Recorded by Interventionist
Time Frame: Week 9 (post-intervention)
|
Session attendance will be recorded by the interventionist at each scheduled session.
The percent of participants who are retained throughout the 3 session intervention will be calculated.
|
Week 9 (post-intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Photoprotective Behaviors Assessed With the Sun Habits Survey
Time Frame: Weeks 1 (baseline), 3,5,7,9,13
|
"These next questions ask about what you have done in the past month if you were outdoors in the sun for 15 minutes or more.
How often did you..." Minimum value = 1; Maximum value = 5; Higher scores indicate a better outcome
|
Weeks 1 (baseline), 3,5,7,9,13
|
|
Photoprotective Behaviors Assessed With the PALE Questionnaire
Time Frame: Weeks 1 (baseline), 3,5,7,9,13
|
Protection-Adjusted Length of Exposure Index (PALE) Assesses photoprotective behavior during reported activities to yield daily minutes of unprotected sun exposure during each time frame
|
Weeks 1 (baseline), 3,5,7,9,13
|
|
Skin Self-exam Occurrence Assessed Via Questionnaire
Time Frame: Weeks 1 (baseline), 3,5,7,9,13
|
Number of participants who received a skin self-exam during each time frame
|
Weeks 1 (baseline), 3,5,7,9,13
|
|
Skin Self-exam Occurrence Assessed Via Diary
Time Frame: Weeks 1 (baseline), 3,5,7,9,13
|
Number of participants who received a skin self-exam during each time frame interval
|
Weeks 1 (baseline), 3,5,7,9,13
|
|
Sunburn Occurrence Assessed Via Diary
Time Frame: Weeks 1 (baseline), 3,5,7,9,13
|
Number of participants who got a sunburn during each time frame interval
|
Weeks 1 (baseline), 3,5,7,9,13
|
|
Sunburn Occurrence Assessed Via Questionnaire
Time Frame: Weeks 1 (baseline), 3,5,7,9,13
|
Number of participants who received a sunburn during each time frame.
|
Weeks 1 (baseline), 3,5,7,9,13
|
|
Ultraviolet Radiation (UVR) Exposure Assessed Via Dosimeter Device
Time Frame: Weeks 1 (baseline),9,13
|
Change of weekly average UV intake from Week 1 (baseline) to Week 9 (post-intervention) and from Week 9 to Week 13 (1-month follow up)
|
Weeks 1 (baseline),9,13
|
|
Ultraviolet Radiation (UVR) Exposure Assessed Via PALE Questionnaire
Time Frame: Weeks 1 (baseline), 3,5,7,9,13
|
Protection-Adjusted Length of Exposure Index (PALE) Assesses UVR exposure during reported activities to yield daily minutes of unprotected sun exposure during each time frame
|
Weeks 1 (baseline), 3,5,7,9,13
|
|
Degree of Tan on Skin Assessed Via Reflectance Spectroscopy
Time Frame: Weeks 1 (baseline),9,13
|
Mean degree of tan on skin assessed via reflectance spectroscopy of 4 different body parts (exposed wrist, outer arm, chin, and face) at each time frame.
Measurements were taken using a spectrophotometer to quantify skin color.
Melanin index values were recorded, with a higher value representing more melanin in the skin (i.e., darker skin).
|
Weeks 1 (baseline),9,13
|
|
Photoprotection Behavior Changes Assessed Via Questionnaire
Time Frame: Weeks 1,9,13
|
Mean difference for each photoprotection behavior from Week 1 (pre-intervention) to Week 9 (post-intervention) and from Week 9 to Week 13 (1 month follow-up). "These next questions ask about what you have done in the past month if you were outdoors in the sun for 15 minutes or more. How often did you..." Minimum value = 1; Maximum value = 5; A higher mean difference indicates a better outcome |
Weeks 1,9,13
|
|
Skin Self-exam Behavior Changes
Time Frame: Weeks 1,9,13
|
Mean difference for frequency of skin self-exam and thoroughness of skin self-exam (measured by number of body parts examined) from Week 1 (pre-intervention) to Week 9 (post-intervention) and from Week 9 to Week 13 (1 month follow-up). (SSE = skin self-exam) Change in frequency of SSE: "In the past month, how often did you check your skin for any new or changed moles or growths?" 1 = SSE less than once a month, 2 = SSE once a month, 3 = SSE more than once a month; higher mean difference indicates a better outcome. Change in thoroughness of SSE: "In the past month, which of the body parts listed below were checked for any new or changed moles or growths" Minimum value = 0 (checked 0 body parts during SSE); Maximum value = 15 (checked 15 body parts during SSE); higher mean difference indicates a better outcome |
Weeks 1,9,13
|
|
Acceptability of Intervention Assessed Via Questionnaire
Time Frame: Week 9
|
"In these next 15 questions, we want to learn more about your thoughts about what you learned through the FLARE sessions you've had with us in-person and via WebEx or phone. Please indicate how much you agree with each statement." 15 total constructs summed, each was on the same 5 point Likert scale (1 = Strongly Disagree, 5 = Strongly Agree). Minimum value = 1; Maximum Value = 75; higher score means a better outcome (better acceptability) |
Week 9
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Glanz K, Yaroch AL, Dancel M, Saraiya M, Crane LA, Buller DB, Manne S, O'Riordan DL, Heckman CJ, Hay J, Robinson JK. Measures of sun exposure and sun protection practices for behavioral and epidemiologic research. Arch Dermatol. 2008 Feb;144(2):217-22. doi: 10.1001/archdermatol.2007.46.
- Weinstock MA, Risica PM, Martin RA, Rakowski W, Smith KJ, Berwick M, Goldstein MG, Upegui D, Lasater T. Reliability of assessment and circumstances of performance of thorough skin self-examination for the early detection of melanoma in the Check-It-Out Project. Prev Med. 2004 Jun;38(6):761-5. doi: 10.1016/j.ypmed.2004.01.020.
- Gwadry-Sridhar F, Guyatt GH, Arnold JM, Massel D, Brown J, Nadeau L, Lawrence S. Instruments to measure acceptability of information and acquisition of knowledge in patients with heart failure. Eur J Heart Fail. 2003 Dec;5(6):783-91. doi: 10.1016/s1388-9842(03)00158-2.
- Kothe EJ, Mullan BA. Acceptability of a theory of planned behaviour email-based nutrition intervention. Health Promot Int. 2014 Mar;29(1):81-90. doi: 10.1093/heapro/das043. Epub 2012 Aug 31.
- Gage H, Grainger L, Ting S, Williams P, Chorley C, Carey G, Borg N, Bryan K, Castleton B, Trend P, Kaye J, Jordan J, Wade D. Specialist rehabilitation for people with Parkinson's disease in the community: a randomised controlled trial. Southampton (UK): NIHR Journals Library; 2014 Dec. Available from http://www.ncbi.nlm.nih.gov/books/NBK263782/
- Stump, T. K., Aspinwall, L. G., Taber, J. M., Edwards, R., & Leachman, S. A. Validation of the Protection-Adjusted Length of Exposure (PALE) Index - A New Self-Report Measure of UVR Exposure (2014, April). Paper presented at the annual meeting of the Society of Behavioral Medicine, Philadelphia, PA.
- Wu YP, Boucher K, Hu N, Hay J, Kohlmann W, Aspinwall LG, Bowen DJ, Parsons BG, Nagelhout ES, Grossman D, Mooney K, Leachman SA, Tercyak KP. A pilot study of a telehealth family-focused melanoma preventive intervention for children with a family history of melanoma. Psychooncology. 2020 Jan;29(1):148-155. doi: 10.1002/pon.5232. Epub 2019 Nov 10.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB_00090292
- K07CA196985 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.